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INTRODUCTION
Obesity is a well-known risk factor for breast cancer, and
obese women are likely to have metastatic breast cancer when
they are first diagnosed, and to have a poor prognosis regard-
less of their menopausal status (1, 2). Although the exact
mechanism remains to be determined, the hormonal changes
associated with obesity are considered to be responsible for
this relationship, with particular emphasis being placed on
the increased production of estrogen. Adipose tissue is well
established that the source of estrogen production through
aromatization of androgens which is derived from the adrenal
gland (3). However, according to recent studies, the contri-
bution to the development of breast cancer from obesity is
not fully explained by increased estrogen levels only (4, 5).
Adipose tissue is not only a passive reservoir for energy
storage but is now known to express and secrete a variety of
metabolites, hormones, and cytokines, known as adipocyto-
kines, which act at both the local and systemic level. These
adipocytokines include leptin, adiponectin, complement com-
ponents, plasminogen activator inhibitor-1, tumor necrosis
factor- (TNF- ), interleukin-6 (IL-6), proteins of the renin-
angiotensin system, and resistin (6).
Adiponectin is secreted from adipocytes exclusively and it
has been established that plasma adiponectin concentration
is inversely correlated with the incidence of obesity, type 2
diabetes, and cardiovascular disease (7-9). Adiponectin was
shown to have anti-inflammatory activity, a protective effect
against metabolic disorders resulting from the insulin resis-
tance, and improve endothelial dysfunction (10-12). 
Resistin, named for resistance to insulin, is a unique sig-
nalling molecule secreted from adipocytes. Circulating resistin
levels are decreased by the anti-diabetic drug rosiglitazone,
and increased in diet-induced and genetic forms of obesity. In
addition, treatment of normal mice with recombinant resistin
impairs glucose tolerance and insulin action. Insulin-stimu-
lated glucose uptake by adipocytes is enhanced by neutraliza-
tion of resistin and is reduced by resistin treatment. Thus,
resistin may serve as a hormone that potentially links obesity
to insulin resistance (13). However, the studies performed on
humans lack coherence between the results, and further stud-
ies are needed to ascertain the role of resistin (14, 15).
Interestingly, several recent case-control studies have shown
that decreased adiponectin levels are associated with the inci-
dence of breast cancer, but the correlation between serum
adiponectin and breast cancer risk is not clear yet, and the
molecular basis for the link remains poorly understood (16-
18). To our knowledge, the association of resistin with can-
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Relationship of Serum Adiponectin and Resistin Levels with Breast
Cancer Risk
Obesity is one of the well-known risk factors of breast cancer. We evaluated the rela-
tionship between serum adiponectin and resistin levels and breast cancer risk in 41
biopsy-proven breast cancer patients and 43 age- and body mass index-matched
controls. The mean serum adiponectin level was lower in the breast cancer group
than the control group (6.93± ±3.2  g/mL, vs. 7.60± ±3.5  g/mL), but this difference
did not reach statistical significance (p=0.37). There was a statistically significant
difference in serum resistin levels between the groups (breast cancer group 5.23± ±
6.9 ng/mL vs. control 1.46± ±2.0 ng/mL; p<0.001). The risk of breast cancer was
significantly increased in the highest tertile group for serum resistin level compared
to the lowest tertile group (adjusted odds ratio 2.77 [95% CI 1.40-5.50]). The lymph
node metastasis was significantly increased in the patients with less than the median
adiponectin level (p=0.017). In the patients whose resistin level was higher than the
median, the frequency of tumor with the highest histological grade was significant-
ly increased (p=0.025). In conclusions, both the low serum adiponectin levels and
high resistin levels are likely to be associated with increased breast cancer risk in
Korean women.
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cer has not been reported until now.
In this case-control study, we examined the relationship of
serum adiponectin and resistin level with breast cancer risk




From January 2005 to December 2005, forty-one female
patients who were newly diagnosed with breast cancer and
surgically treated at a University Hospital were enrolled into
the study as patients group. Among women who visited the
same hospital for annual health examinations, we selected 43
women with normal mammographic findings and no previ-
ous history of any kind of cancer as age and body mass index-
matched controls.
Anthropometric measurement and blood tests
Body weight was measured with light clothing on with
up to 0.1 kg precision. Height was measured up to 0.1 cm.
The blood samples were collected within the week before
surgery. Plasma glucose, adiponectin, and resistin concentra-
tions were measured after overnight fasting for more than
12 hr. Plasma adiponectin was measured using human adi-
ponectin ELISA kit (AdipoGen, Inc., Seoul, Korea) with a
measurement range of 0.1-32 ng/mL, sensitivity of 0.1 ng/
mL, intra-assay reproducibility of 96.5%, and inter-assay repro-
ducibility of 95.6%. Plasma resistin level was measured using
human resistin ELISA kit (AdipoGen, Inc., Seoul, Korea) with
a measurement range of 0.1-8  g/mL, sensitivity of 0.1  g/
mL, intra-assay reproducibility of 96.3%, and inter-assay repro-
ducibility of 94.4%.
Clinicopathologic characteristics of tumor
Patients with breast cancer were classified according to the
size of tumors (>2 cm or ≤2 cm) and status of lymph node
metastasis (presence or absence). Histological grading of breast
cancer was based on the Bloom-Richardson grading system.
The status of estrogen receptor and progesterone receptor were
analyzed by imminohistochemical staining (DAKO, Carpin-
teria, CA, U.S.A.). 
Statistical analysis
Data are presented as means±S.D. Independent t-test was
used to compare variables between case and control group
except for menopausal status (chi-square test). To determine
the risk of breast cancer according to the tertiles of plasma
adiponectin and resistin levels, a multiple logistic regression
model was constructed. The correlation of plasma adiponectin
or resistin concentration with clinicopathologic characteris-
tics of tumors was analyzed by chi-square test. Pearson’s cor-
relation coefficients were used to determine the relationships
between plasma adiponectin, resistin, glucose, body mass
index, and age. A log transformation of plasma resistin levels
was carried out to achieve normal distribution. The level of
significance was set at p<0.05 (two-tailed). Statistical calcu-
lations were performed using SPSS for Windows V11.0 (SPSS
Inc., Chicago, IL, U.S.A.). 
RESULTS
Comparison of adiponectin and resistin levels 
There was no significant difference in age, body mass index,
and percentage of menopausal women (Table 1). The fasting
glucose levels in the control group were significantly lower
than those in the patients group (97.4±20.4 mg/dL vs. 115.2
±30.3 mg/dL). The mean serum adiponectin level was lower
in the breast cancer group than the control group (6.93±3.2
g/mL, vs. 7.60±3.5  g/mL), but this difference did not
reach statistical significance (p=0.37). There was a statisti-
cally significant difference in serum resistin levels between
the groups (breast cancer group 5.23±6.9 ng/mL vs. control
1.46±2.0 ng/mL; p<0.001) (Fig. 1).
When serum adiponectin and resistin levels were compared
in cases and controls according to menopausal status, serum
resistin levels were significantly higher in the breast cancer
group in both pre- and post-menopausal women (p=0.02,
p=0.002; respectively). However, there was no significant
difference in serum adiponectin levels between cases and con-
trols in either pre- or post-menopausal women (p=0.22, p=
0.89; respectively) (Table 1).
Cases (n=41) Controls (n=43) p
Age (yr) 47.4±9.0 47.8±6.0 0.95
Body mass index (kg/m
2) 23.7±3.7 23.7±3.0 0.99
Postmenopausal women (No.) 20 (48.8%) 17 (39.5%) 0.39
Fasting blood glucose (mg/dL) 115.2±30.0 97.4±20.4 0.01
Adiponectin ( g/mL) 6.93±3.2 7.60±3.5 0.37
Premenopausal women  7.13±3.2 8.68±4.0 0.22
(n=35)
Postmenopausal women  6.77±3.3 6.89±3.0 0.89
(n=49)
Resistin (ng/mL) 5.23±6.9 1.46±2.0 <0.001*
Premenopausal women  5.80±7.7 1.85±2.2 0.02*
(n=35)
Postmenopausal women 4.79±6.5 1.20±1.9 0.002*
(n=49)
Table 1. Clinical characteristics of cases and controls (mean±
SD)
*Resistin level was transformed logarithmically before analysis.Adiponectin and Resistin Levels and Breast Cancer Risk 119
Odds ratio of breast cancer according to tertiles of adipo-
nectin or resistin levels 
We estimated the odds ratio of breast cancer according to
tertiles of adiponectin or resistin level using logistic regression
analysis (Table 2). Those in the lowest tertile of plasma adipo-
nectin had an odds ratio for highest tertile of 0.92 (95% CI
0.46-1.81) after being adjusted for age, body mass index, status
of menopause, fasting glucose level, and plasma resistin levels.
The risk of breast cancer was significantly increased in the
highest tertile group for plasma resistin level compared to the
lowest tertile group (odds ratio 2.17 [95% CI 1.24-3.79]),
and this significance remained after being adjusted for age,
body mass index, status of menopause, serum glucose and
adiponectin (adjusted odds ratio 2.77 [95% CI 1.40-5.50]).
Serum adiponectin levels and clinicopathological charac-
teristics of tumors 
We divided patients into two groups by the median level
of adiponectin (7.08  g/mL), to investigate the relationship
between serum adiponectin levels and clinicopathological
characteristics of tumor (Table 3). No significant difference
was found in the frequency of large sized or highly differen-
tiated tumors, or status of progesterone receptor. The lymph
node metastasis (p=0.017) and negativity of estrogen recep-
tor (p=0.032) were significantly increased in the patients with
less than the median adiponectin level.
Serum resistin levels and clinicopathological characteris-
tics of tumors 
The patients were divided into the two groups according
to the plasma resistin level. The cutoff value was defined as
2.42 ng/mL, the median levels of plasma resistin concentra-
tion of the patients group. Comparing with two groups, there
was no significant difference in frequency of large tumors
(>2 cm), status of lymph node metastasis, or estrogen and
















































Variable OR (95% CI)
Adiponectin
Model 1: adiponectin only 0.96 (0.57-1.64)
Model 2: adiponectin+covariates in Table 1 0.97 (0.51-1.83)
Model 3: adiponectin+resistin+covariates 0.92  (0.46-1.81)
in Table 1
Resistin*
Model 1: resistin only 2.17 (1.24-3.79)
Model 2: resistin+covariates in Table 1 2.75 (1.39-5.44)
Model 3: adiponectin+resistin+covariates 2.77  (1.40-5.50)
in Table 1
Table 2. Multiple logistic regression-derived adjusted odds ratio
(ORs) and 95% confidence interval (CI) for breast cancer for a
change in serum adiponectin and resistin of 1 tertile in controls
*Resistin level was transformed logarithmically before analysis.





≤2 cm 13 (61.9) 8 (40.0) 0.161 8 (38.1) 13 (65.0) 0.085
>2 cm 8 (38.1) 12 (60.0) 13 (61.9) 7 (35.0)
Lymph node metastasis
Negative 15 (71.4) 6 (33.3) 0.017 9 (45.0) 12 (63.2) 0.256
Positive 6 (28.6) 12 (66.7) 11 (55.0) 7 (36.8)
Histological grade
1+2 13 (61.9) 15 (75.0) 0.368 11 (52.4) 17 (85.0) 0.025
3 8 (38.1) 5 (33.3) 10 (47.6) 3 (15.0)
Estrogen receptor
Positive 10 (47.6) 3 (15.8) 0.032 7 (35.0) 6 (30.0) 0.736
Negative 11 (52.4) 16 (84.2) 13 (65.0) 14 (70.0)
Progesterone receptor
Positive 14 (66.7) 7 (36.8) 0.059 11 (55.0) 10 (50.0) 0.752
Negative 7 (33.3) 12 (63.2) 9 (45.0) 10 (50.0)
Table 3. Association between serum adiponectin or resistin lev-
els and clinicopathological characteristics in breast cancer pa-
tients (number, %)
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ents whose plasma resistin level was higher than the median
value, the frequency of tumor with the highest histological
grade was significantly increased (p=0.025).
Relationship between adiponectin, resistin and other
variables 
We investigated whether there was any relationship between
the plasma adiponectin, resistin, glucose, body mass index
and age. No significant correlation was found between plas-
ma adiponectin and resistin concentration (control group r=
0.14, p=0.391; patients group r=-0.169, p=0.291). Plasma
glucose level, body mass index and age did not have any signi-
ficant relationship with plasma adiponectin or resistin levels.
DISCUSSION
Since the relationship of obesity to several forms of cancer
has been known for a long time, researchers were trying to
discover the possible role of adipocytokines in the regulation
of carcinogenesis as another link between obesity and cancer.
Adiponectin recently gained interest in correlation with can-
cer, and was inversely and independently associated with bre-
ast, endometrial, gastric, prostate and colorectal cancer in
case control studies (16-22). In our study, adiponectin level
was lower in the breast cancer group than the control group,
but this difference did not reach statistical significance. Plas-
ma adiponectin levels were also negatively associated with
progression of histological grade and tumor stage in patients
with breast, prostate and gastric cancer (17, 20, 21). In this
study, only the frequency of lymph node metastasis out of
the several clinicopathological characteristics of tumor was
significantly increased in the patients with low plasma adi-
ponectin levels.
It has been reported that obesity-related breast cancer is
more often estrogen receptor positive than is the general case,
but this has not been a consistent finding (23). Our study
showed that the frequency of the tumors with negative estro-
gen receptor was significantly increased in the patients with
less than the median adiponectin level. However, in the pre-
vious study, the status of estrogen receptor and progesterone
receptor did not affect the adiponectin levels in breast cancer
patients, and no significant correlation was observed between
the serum adiponectin and estrone levels in postmenopausal
women (17, 18). 
One possible mechanism explaining associations between
obesity and cancer other than estrogen is hyperinsulinemia
or insulin resistance. Insulin enhances the activity of insulin-
like growth factor-1 (IGF-1), and high levels of circulating
IGF-1 are correlated with risk of development of breast can-
cer (24). However, Mantzoros et al. (16) reported that asso-
ciations between serum adiponectin and breast cancer risk
were independent of possible effects of major components of
the IGF system, leptin, and body mass index.
The molecular mechanism of the contributions of low
serum adiponectin levels to carcinogenesis and progression
of tumor is currently unknown. Recently, adiponectin has
been reported to induce activation of caspase enzymes which
leads to endothelial cell apoptosis, and the reduction of tumor
neovascularization (25). In addition, adiponectin has a direct
inhibitory effect on proliferation of vascular smooth muscle
cells and myelomonocytic progenitors (26). In a recent study,
adiponectin has been reported to induce growth arrest and
apoptosis of MDA-MB-231 breast cancer cells (27). These
results are speculated to infer that adiponectin may promote
apoptosis directly by activation of apoptotic enzymes in the
caspase cascade or modulation of expression of apoptosis-
related genes. 
To our knowledge, there has not been any report about the
association between cancer and resistin. However, this study
showed that the high level of resistin was associated with the
risk of breast cancer, and this relationship was independent
of age, body mass index, status of menopause, serum glucose
and adiponectin. Moreover, in the patients whose plasma
resistin level was higher than the median, the frequency of
tumor with the highest histological grade was significantly
increased. These results suggest the possibility that high
serum resistin levels might be another adiponcytokine that
contribute to increase breast cancer risk.
The relationship of serum resistin with insulin resistance
is not established yet, because of discord among the previous
human studies. Even though elevated blood glucose levels
possibly affect proliferation of the breast cancer cell line, the
logistic regression analysis showed that the relationship bet-
ween the risk of breast cancer and serum resistin was inde-
pendent of the fasting blood glucose level and adiponectin,
which was inversely associated with insulin resistance.
Because the previous studies revealed that resistin is exp-
ressed not only from adipose tissue but also from monocytes
and macrophages, and correlated with C-reactive protein,
TNF- , and IL-6 directly, the role of resistin as another marker
of inflammation has received growing interest (28). Chronic
inflammation is known to be one of the causes of cancer devel-
opment, and inflammation may be represented by biomark-
ers of early pathologic changes in breast cells and be associ-
ated with risk for the development of breast cancer (29, 30).
Thus, the correlation between plasma resistin levels and breast
cancer risk might be partly explained by inflammation.
There are several limitations of this study. The number of
study subjects was limited, the risk factors of breast cancer such
as family history of breast cancer, age of the menarche, and
birth history were not controlled, and the causal relationship
could not be revealed due to the case-control study design.
A study about the precise mechanism of the relationship of
adiponectin and resistin with breast cancer risk, a large-scaled
prospective study should be supported in the future.
In conclusion, the low serum adiponectin level and highresistin level might be associated with increased breast can-
cer risk, but only the difference of serum resistin levels reached
statistical significance between breast cancer and control group.
The clinicopathologic characteristics of the tumor suggest-
ed that these adipokines might influence the progression of
breast cancer.
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